OncLive TV

Joseph Mikhael, MD, discusses unmet needs that remain to be addressed in the treatment of patients with multiple myeloma.

Michael Richardson, MD, discusses escalating uterine cancer rates among Asian Americans.

Minesh Mehta, MD, discusses how MRI-guided adaptive radiation therapy systems may improve disease outcomes in cancer care.

Ruben Olivares, MD, discusses the evolving role for focal radiation therapy in the management of prostate cancer.

Phillip J. Koo, MD, discusses the use of PSMA PET imaging in prostate cancer.

Don S. Dizon, MD, on the prevalence of sexual complications in patients with breast cancer.

Gottfried Konecny, MD, discusses the MIRASOL trial that evaluated mirvetuximab soravtansine in FRα-positive platinum-resistant recurrent ovarian cancer.

Steven E. Finkelstein, MD, DABR, FACRO, on advancing radiation oncology and updates from the 2024 ACRO Summit.

Wenxin (Vincent) Xu, MD, on evolving systemic therapy and the utilization of biomarkers in the treatment of renal cell carcinoma.

Daniel Spratt, MD, discusses the integration of metastasis-directed therapy and hypofractionation in prostate cancer.

Jennifer R. Brown, MD, PhD, discusses results from a genomic analysis of responses with pirtobrutinib in patients with chronic lymphocytic leukemia.

Ariel Grajales-Cruz, MD, discusses research elucidating the role of teclistamab monotherapy for patients with relapsed/refractory multiple myeloma.

Daniel Spratt, MD, discusses the use of radiation therapy in low- and high-risk prostate cancer.

Arya Amini, MD, discusses cardiac toxicities associated with lung cancer.

Wenxin (Vincent) Xu, MD, discusses treatment decision-making in patients with renal cell carcinoma.

Philip J. Koo, MD, discusses the treatment of patients with prostate cancer throughout the different stages of their disease.

Reshma L. Mahtani, DO, discusses how the expansion of HER2-targeted agents has impacted the management of HER2-positive breast cancer.

Patrick I. Borgen, MD, discusses the ongoing debate of routine MRI testing in early-stage breast cancer.

Gottfried E. Konecny, MD, discusses the FDA approval of mirvetuximab soravtansine for patients with FRα-positive, platinum-resistant ovarian cancer.

Anthony V. D'Amico, MD, PhD, on the advancements in high-risk prostate cancer diagnosis and management

Henry Kuerer, MD, PhD, FACS, CMQ, on significant advancements in neoadjuvant systemic therapies in breast cancer treatment

Anna Lee, MD, MPH, discusses key takeaways from a presentation on managing head and neck cancers that was given at the 2024 ACRO Summit.

Adrianna Masters, MD, PhD, discusses pivotal events from the 2024 ACRO Summit, emphasizing the importance of mentorship in radiation oncology.

Kari Hacker, MD, PhD, discusses the proportion of HER2-expressing endometrial cancers eligible for HER2-targeted antibody-drug conjugate treatment.

Janos L. Tanyi, MD, PhD, discusses the use of pafolacianine sodium injections during cytoreductive surgery in FRα–positive ovarian cancer.

Elias Jabbour, MD, discusses the FDA approval of ponatinib plus chemotherapy for Philadelphia chromosome–positive acute lymphoblastic leukemia.

Francisco Hernandez-Ilizaliturri, MD, discusses the unique potential advantages of the radiotherapeutic iopofosine I 131 in Waldenström macroglobulinemia.

Mary-Ellen Taplin, MD, discusses strategies to mitigate health care inequities in prostate cancer.

Emmanuel Antonarakis, MD, discusses the significance of TALPRO-3, EVOPAR, and AMPLITUDE trials on the metastatic prostate cancer treatment paradigm.

Reshma L. Mahtani, DO, discusses unique challenges women may face when transitioning between different career roles within oncology.